171 related articles for article (PubMed ID: 27714671)
1. BRCA1 and MDM2 as independent blood-based biomarkers of head and neck cancer.
Bhowmik A; Das S; Bhattacharjee A; Choudhury B; Naiding M; Ghosh SK; Choudhury Y
Tumour Biol; 2016 Oct; ():. PubMed ID: 27714671
[TBL] [Abstract][Full Text] [Related]
2. MDM2 and TP53 Polymorphisms as Predictive Markers for Head and Neck Cancer in Northeast Indian Population: Effect of Gene-Gene and Gene-Environment Interactions.
Bhowmik A; Das S; Bhattacharjee A; Choudhury B; Naiding M; Deka S; Ghosh SK; Choudhury Y
Asian Pac J Cancer Prev; 2015; 16(14):5767-72. PubMed ID: 26320449
[TBL] [Abstract][Full Text] [Related]
3. Identification of p53-target genes in human papillomavirus-associated head and neck cancer by integrative bioinformatics analysis.
Bouzid A; Al Ani M; de la Fuente D; Al Shareef ZM; Quadri A; Hamoudi R; Al-Rawi N
Front Oncol; 2023; 13():1128753. PubMed ID: 37081989
[TBL] [Abstract][Full Text] [Related]
4. DNA repair pathways to regulate response to chemoradiotherapy in patients with locally advanced head and neck cancer.
Cirauqui B; Margelí M; Quiroga V; Quer A; Karachaliou N; Chaib I; Ramírez JL; Muñoz A; Pollán C; Planas I; Drozdowsky A; Rosell R
Tumour Biol; 2016 Oct; 37(10):13435-13443. PubMed ID: 27465548
[TBL] [Abstract][Full Text] [Related]
5. XI-011 enhances cisplatin-induced apoptosis by functional restoration of p53 in head and neck cancer.
Roh JL; Park JY; Kim EH
Apoptosis; 2014 Nov; 19(11):1594-602. PubMed ID: 25113507
[TBL] [Abstract][Full Text] [Related]
6. Loss of MTBP expression is associated with reduced survival in a biomarker-defined subset of patients with squamous cell carcinoma of the head and neck.
Vlatković N; El-Fert A; Devling T; Ray-Sinha A; Gore DM; Rubbi CP; Dodson A; Jones AS; Helliwell TR; Jones TM; Boyd MT
Cancer; 2011 Jul; 117(13):2939-50. PubMed ID: 21692053
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of ATM and BRCA1 Predicts Poor Outcome in Head and Neck Cancer: Implications for ATM-Targeted Therapy.
Wang YC; Lee KW; Tsai YS; Lu HH; Chen SY; Hsieh HY; Lin CS
J Pers Med; 2021 May; 11(5):. PubMed ID: 34068585
[No Abstract] [Full Text] [Related]
8. MDM2 309 polymorphism predicts outcome in platinum-treated locally advanced head and neck cancer.
Vivenza D; Gasco M; Monteverde M; Lattanzio L; Syed N; Colantonio I; Denaro N; Natoli G; Comino A; Russi E; Merlano M; Crook T; Lo Nigro C
Oral Oncol; 2012 Jul; 48(7):602-7. PubMed ID: 22356895
[TBL] [Abstract][Full Text] [Related]
9. p53 and MDM2 immunostaining in pulmonary blastomas and bronchogenic carcinomas.
Pacinda SJ; Ledet SC; Gondo MM; Langston C; Brown RW; Carmona PA; Franklin RB; Roggli VL; Cagle PT
Hum Pathol; 1996 Jun; 27(6):542-6. PubMed ID: 8666362
[TBL] [Abstract][Full Text] [Related]
10. Identifying potential prognostic biomarkers in head and neck cancer based on the analysis of microRNA expression profiles in TCGA database.
Wang X; Yin Z; Zhao Y; He M; Dong C; Zhong M
Mol Med Rep; 2020 Mar; 21(3):1647-1657. PubMed ID: 32016476
[TBL] [Abstract][Full Text] [Related]
11. RITA plus 3-MA overcomes chemoresistance of head and neck cancer cells via dual inhibition of autophagy and antioxidant systems.
Shin D; Kim EH; Lee J; Roh JL
Redox Biol; 2017 Oct; 13():219-227. PubMed ID: 28582730
[TBL] [Abstract][Full Text] [Related]
12. Detection of p53 and MDM2 protein expression in head and neck carcinogenesis.
Girod SC; Cesarz D; Fischer U; Krueger GR
Anticancer Res; 1995; 15(4):1453-7. PubMed ID: 7654034
[TBL] [Abstract][Full Text] [Related]
13. A Nomogram for Predicting the Risk of Bone Metastasis in Newly Diagnosed Head and Neck Cancer Patients: A Real-World Data Retrospective Cohort Study From SEER Database.
Huang C; He J; Ding Z; Li H; Zhou Z; Shi X
Front Genet; 2022; 13():865418. PubMed ID: 35706444
[No Abstract] [Full Text] [Related]
14. Effects of the single nucleotide polymorphism at MDM2 309 on breast cancer patients with/without BRCA1/2 mutations.
Nechushtan H; Hamburger T; Mendelson S; Kadouri L; Sharon N; Pikarsky E; Peretz T
BMC Cancer; 2009 Feb; 9():60. PubMed ID: 19226467
[TBL] [Abstract][Full Text] [Related]
15. [Interaction between p53 and MDM2 in human lung cancer cells].
Rybárová S; Hodorová I; Vecanová J; Muri J; Mihalik J
Klin Onkol; 2014; 27(1):33-7. PubMed ID: 24635435
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic accuracy of DNA methylation for head and neck cancer varies by sample type and number of markers tested.
Ji X; Guan C; Jiang X; Li H
Oncotarget; 2016 Nov; 7(48):80019-80032. PubMed ID: 27683120
[TBL] [Abstract][Full Text] [Related]
17. Expression of p21/waf1 in oral squamous cell carcinomas--correlation with p53 and mdm2 and cellular proliferation index.
Ng IO; Lam KY; Ng M; Regezi JA
Oral Oncol; 1999 Jan; 35(1):63-9. PubMed ID: 10211312
[TBL] [Abstract][Full Text] [Related]
18. Risk of head and neck cancer in relation to blood inflammatory biomarkers in the Swedish AMORIS cohort.
Yang Y; Liang Y; Sadeghi F; Feychting M; Hamar N; Fang F; Zhang Z; Liu Q
Front Immunol; 2023; 14():1265406. PubMed ID: 37876941
[TBL] [Abstract][Full Text] [Related]
19. Low level of BRCA2 in peripheral blood lymphocytes is associated with an increased risk for head and neck squamous cell carcinoma (HNSCC) in a population of North-East India: a case-control study.
Das S; Bhowmik A; Bhattacharjee A; Choudhury B; Naiding M; Dhar B; Laskar AK; Pandit J; Ghosh SK; Choudhury Y
Ecancermedicalscience; 2023; 17():1503. PubMed ID: 37113717
[TBL] [Abstract][Full Text] [Related]
20. Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers.
Copson ER; White HE; Blaydes JP; Robinson DO; Johnson PW; Eccles DM
BMC Cancer; 2006 Mar; 6():80. PubMed ID: 16563154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
